In the last decade we have seen a progressive trend across the pharmaceutical industry, with big block-buster drugs gradually becoming less prevalent, as well as a shift towards smaller-volume therapies. Although this change has been necessitated by the discovery pipeline, Stuart Needleman at Piramal Pharma Solution shows how targeted therapies and personalised approaches have profound supply chain implications.